Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion

Journal of Virology

Volumn 83, Issue 4, 2009, Pages 1546-1554

  Wagenaar, Timothy R ^a,b   Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A56 PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; K2 PROTEIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ANIMAL CELL; ARTICLE; CELL FUSION; CELL STRUCTURE; ENZYME ACTIVITY; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; REPORTER GENE; STABLE EXPRESSION; SYNCYTIUM; VACCINIA VIRUS; VIRUS ENTRY; VIRUS REPLICATION;

CELL FUSION; CELL LINE; GENES, REPORTER; HUMANS; LUCIFERASES; PLAQUE ASSAY; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS INTERNALIZATION; VIRUS REPLICATION;

ANIMALIA; VACCINIA VIRUS;

EID: 59649101872     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01684-08     Document Type: Article

References (55)

1. Anton, L. C., U. Schubert, I. Bacik, M. F. Princiotta, P. A. Wearsch, J. Gibbs, P. M. Day, C. Realini, M. C. Rechsteiner, J. R. Bennink, and J. W. Yewdell. 1999. Intracellular localization of proteasomal degradation of a viral antigen. J. Cell Biol. 146:113-124.
2. Armstrong, J. A., D. H. Metz, and M. R. Young. 1973. The mode of entry of vaccinia virus into L cells. J. Gen. Virol. 21:533-537.
3. Bisht, H., A. S. Weisberg, and B. Moss. 2008. Vaccinia virus L1 protein is required for cell entry and membrane fusion. J. Virol. 82:8687-8694.
4. Blasco, R., and B. Moss. 1991. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-dalton outer envelope protein. J. Virol. 65:5910-5920.
5. Brown, E., T. G. Senkevich, and B. Moss. 2006. Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related l1 protein. J. Virol. 80:9455-9464.
6. Brum, L. M., P. C. Turner, H. Devick, M. T. Baquero, and R. W. Moyer. 2003. Plasma membrane localization and fusion inhibitory activity of the cowpox virus serpin SPI-3 require a functional signal sequence and the virus encoded hemagglutinin. Virology 306:289-302.
7. Buck, C. B., D. V. Pastrana, D. R. Lowy, and J. T. Schiller. 2004. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78:751-757.
8. Carter, G. C., M. Law, M. Hollinshead, and G. L. Smith. 2005. Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. J. Gen. Virol. 86:1279-1290.
9. Chang, A., and D. H. Metz. 1976. Further investigations on the mode of entry of vaccinia virus into cells. J. Gen. Virol. 32:275-282.
10. Christen, L., J. Seto, and E. G. Niles. 1990. Superinfection exclusion of vaccinia virus in virus-infected cell cultures. Virology 174:35-42.
11. Condit, R. C. 2007. Vaccinia, Inc. - probing the functional substructure of poxviral replication factories. Cell Host Microbe 2:205-207.
12. Doms, R. W., R. Blumenthal, and B. Moss. 1990. Fusion of intra- and extracellular forms of vaccinia virus with the cell membrane. J. Virol. 64:4884-4892.
13. Earl, P. L., J. L. Americo, and B. Moss. 2003. Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J. Virol. 77:10684-10688.
14. Earl, P. L., C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss. 1994. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 68:3015-3026.
15. Earl, P. L., and B. Moss. 1998. Characterization of recombinant vaccinia viruses and their products, p. 16.18.1-16.18.11. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol. 2. Greene Publishing Associates, New York, NY.
16. Flexner, C., A. Hugin, and B. Moss. 1987. Prevention of vaccinia virus infection in immunodeficient nude mice by vector-directed IL-2 expression. Nature 330:259-262.
17. Girgis, N. M., B. C. Dehaven, X. Fan, K. M. Viner, M. Shamim, and S. N. Isaacs. 2008. Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack. J. Virol. 82:4205-4214.
18. Gong, S. C., C. F. Lai, and M. Esteban. 1990. Vaccinia virus induces cell fusion at acid pH and this activity is mediated by the N-terminus of the 14-kDa virus envelope protein. Virology 178:81-91.
19. Hiller, G., and K. Weber. 1985. Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment. J. Virol. 55:651-659.
20. Husain, M., A. S. Weisberg, and B. Moss. 2007. Resistance of a vaccinia virus A34R deletion mutant to spontaneous rupture of the outer membrane of progeny virions on the surface of infected cells. Virology 366:424-432.
21. Ichihashi, Y., and S. Dales. 1971. Biogenesis of poxviruses: interrelationship between hemagglutinin production and polykaryocytosis. Virology 46:533-543.
22. Isaacs, S. N., G. J. Kotwal, and B. Moss. 1992. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. USA 89:628-632.
23. Izmailyan, R. A., C. Y. Huang, S. Mohammad, S. N. Isaacs, and W. Chang. 2006. The envelope G3L protein is essential for entry of vaccinia virus into host cells. J. Virol. 80:8402-8410.
24. Law, K. M., and G. L. Smith. 1992. A vaccinia serine protease inhibitor which prevents virus-induced cell fusion. J. Gen. Virol. 73:549-557.
25. Law, M., G. C. Carter, K. L. Roberts, M. Hollinshead, and G. L. Smith. 2006. Ligand-induced and non-fusogenic dissolution of a viral membrane. Proc. Natl. Acad. Sci. USA 103:5989-5994.
26. Lee, S. L., J. M. Roos, L. C. McGuigan, K. A. Smith, N. Cormier, L. K. Cohen, B. E. Roberts, and L. G. Payne. 1992. Molecular attenuation of vaccinia virus: mutant generation and animal characterization. J. Virol. 66: 2617-2630.
27. Mercer, J., and A. Helenius. 2008. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 320:531-535.
28. Moss, B. 2007. Poxviridae: the viruses and their replication, p. 2905-2946. In D. M. Knipe and P. M. Howley (ed.), Fields virology, vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA.
29. Moss, B. 2006. Poxvirus entry and membrane fusion. Virology 344:48-54.
30. Moss, B., and B. M. Ward. 2001. High-speed mass transit for poxviruses on microtubules. Nat. Cell Biol. 3:E245-E246.
31. Nelson, G. E., T. R. Wagenaar, and B. Moss. 2008. A conserved sequence within the H2 subunit of the vaccinia virus entry/fusion complex is important for interaction with the A28 subunit and infectivity. J. Virol. 82:6244-6250.
32. Nichols, R. J., E. Stanitsa, B. Unger, and P. Traktman. 2008. The vaccinia I2L gene encodes a membrane protein with an essential role in virion entry. J. Virol. 82:10247-10261.
33. Norbury, C. C., D. Malide, J. S. Gibbs, J. R. Bennink, and J. W. Yewdell. 2002. Visualizing priming of virus-specific CD8(+) T cells by infected dendritic cells in vivo. Nat. Immunol. 3:265-271.
34. Nussbaum, O., C. C. Broder, and E. A. Berger. 1994. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantifying cell fusion-dependent reporter gene activation. J. Virol. 68:5411-5422.
35. Ojeda, S., A. Domi, and B. Moss. 2006. Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex. J. Virol. 80:9822-9830.
36. Ojeda, S., T. G. Senkevich, and B. Moss. 2006. Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J. Virol. 80:51-61.
37. Rajagopal, I., B. Y. Ahn, B. Moss, and C. K. Mathews. 1995. Roles of vaccinia virus ribonucleotide reductase and glutaredoxin in DNA precursor biosynthesis. J. Biol. Chem. 270:27415-27418.
38. Seki, M., M. Oie, Y. Ichihashi, and H. Shida. 1990. Hemadsorption and fusion inhibition activities of hemagglutinin analyzed by vaccinia virus mutants. Virology 175:372-384.
39. Senkevich, T. G., and B. Moss. 2005. Vaccinia virus H2 protein is an essential component of a complex involved in virus entry and cell-cell fusion. J. Virol. 79:4744-4754.
40. Senkevich, T. G., S. Ojeda, A. Townsley, G. E. Nelson, and B. Moss. 2005. Poxvirus multiprotein entry-fusion complex. Proc. Natl. Acad. Sci. USA 102:18572-18577.
41. Senkevich, T. G., B. M. Ward, and B. Moss. 2004. Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J. Virol. 78:2357-2366.
42. Shida, H., Y. Hinuma, M. Hatanaka, M. Morita, M. Kidokora, K. Suzuki, T. Maruyama, F. Takahashi-Nishimaki, M. Sugimoto, R. Kitamura, T. Miyazawa, and M. Hayami. 1988. Effects and virulence of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type 1 envelope gene. J. Virol. 62:4474-4480.
43. Smith, G. L., A. Vanderplasschen, and M. Law. 2002. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83:2915-2931.
44. Thompson, J. P., P. C. Turner, A. N. Ali, B. C. Crenshaw, and R. W. Moyer. 1993. The effects of serpin gene mutations on the distinctive pathobiology of cowpox and rabbitpox virus following intranasal inoculaiton of Balb/c mice. Virology 197:328-338.
45. Tooze, J., M. Hollinshead, B. Reis, K. Radsak, and H. Kern. 1993. Progeny vaccinia and human cytomegalovirus particles utilize early endosomal cisternae for their envelopes. Eur. J. Cell Biol. 60:163-178.
46. Townsley, A., T. G. Senkevich, and B. Moss. 2005. The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all pox-viruses that is requried for cell entry and cell-cell fusion. J. Virol. 79:10988-10998.
47. Townsley, A., T. G. Senkevich, and B. Moss. 2005. Vaccinia virus A21 virion membrane protein is required for cell entry and fusion. J. Virol. 79:9458-9469.
48. Townsley, A. C., and B. Moss. 2007. Two distinct low-pH steps promote entry of vaccinia virus. J. Virol. 81:8613-8620.
49. Townsley, A. C., A. S. Weisberg, T. R. Wagenaar, and B. Moss. 2006. Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J. Virol. 80:8899-8908.
50. Turner, P. C., and R. W. Moyer. 1992. An orthopoxvirus serpin-like gene controls the ability of infected cells to fuse. J. Virol. 66:2076-2085.
51. Turner, P. C., and R. W. Moyer. 2006. The cowpox virus fusion regulator proteins SPI-3 and hemagglutinin interact in infected and uninfected cells. Virology 347:88-99.
52. Turner, P. C., and R. W. Moyer. 2008. The vaccinia virus fusion inhibitor proteins SPI-3 (K2) and HA (A56) expressed by infected cells reduce the entry of superinfecting virus. Virology 380:226-233.
53. Wagenaar, T. R., and B. Moss. 2007. Association of vaccinia virus fusion regulatory proteins with the multicomponent entry/fusion complex. J. Virol. 81:6286-6293.
54. Wagenaar, T. R., S. Ojeda, and B. Moss. 2008. Vaccinia virus A56/K2 fusion regulatory protein interacts with the A16 and G9 subunits of the entry fusion complex. J. Virol. 82:5153-5160.
55. Zhou, J., X. Y. Sun, G. J. P. Fernando, and I. H. Frazer. 1992. The vaccinia virus K2L gene encodes a serine protease inhibitor which inhibits cell-cell fusion. Virology 189:678-686.